Redmile Group, LLC Akero Therapeutics, Inc. Transaction History

Redmile Group, LLC

  • $1.53 Billion
  • Q2 2024

A detailed history of Redmile Group, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 1,614,473 shares of AKRO stock, worth $42.6 Million. This represents 2.47% of its overall portfolio holdings.

Number of Shares
1,614,473
Previous 1,858,702 13.14%
Holding current value
$42.6 Million
Previous $47 Million 19.33%
% of portfolio
2.47%
Previous 1.85%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$18.31 - $24.62 $4.47 Million - $6.01 Million
-244,229 Reduced 13.14%
1,614,473 $37.9 Million
Q1 2024

May 15, 2024
BUY
$17.76 - $31.18 $13.3 Million - $23.4 Million
749,226 Added 67.53%
1,858,702 $47 Million
Q4 2023

Feb 14, 2024
SELL
$11.38 - $50.33 $7.99 Million - $35.3 Million
-702,196 Reduced 38.76%
1,109,476 $25.9 Million
Q2 2023

Aug 14, 2023
SELL
$36.89 - $56.88 $8.58 Million - $13.2 Million
-232,717 Reduced 11.38%
1,811,672 $84.6 Million
Q1 2023

May 15, 2023
SELL
$37.27 - $50.24 $21.9 Million - $29.6 Million
-588,523 Reduced 22.35%
2,044,389 $78.2 Million
Q4 2022

Feb 14, 2023
BUY
$33.44 - $54.8 $34.8 Million - $57.1 Million
1,041,827 Added 65.48%
2,632,912 $144 Million
Q3 2022

Nov 14, 2022
BUY
$10.15 - $34.05 $38,570 - $129,389
3,800 Added 0.24%
1,591,085 $54.2 Million
Q2 2022

Aug 15, 2022
SELL
$8.0 - $15.01 $120,000 - $225,150
-15,000 Reduced 0.94%
1,587,285 $15 Million
Q4 2021

Feb 14, 2022
SELL
$19.87 - $26.24 $21.6 Million - $28.5 Million
-1,085,159 Reduced 40.38%
1,602,285 $33.9 Million
Q3 2021

Nov 15, 2021
SELL
$18.65 - $25.46 $2.19 Million - $2.99 Million
-117,500 Reduced 4.19%
2,687,444 $60.1 Million
Q2 2021

Aug 16, 2021
BUY
$24.81 - $32.35 $7.22 Million - $9.42 Million
291,198 Added 11.58%
2,804,944 $69.6 Million
Q1 2021

May 17, 2021
BUY
$24.04 - $34.19 $4.6 Million - $6.54 Million
191,189 Added 8.23%
2,513,746 $72.9 Million
Q4 2020

Feb 16, 2021
SELL
$25.12 - $29.89 $346,656 - $412,482
-13,800 Reduced 0.59%
2,322,557 $59.9 Million
Q3 2020

Nov 16, 2020
BUY
$30.79 - $39.92 $59.9 Million - $77.6 Million
1,944,205 Added 495.78%
2,336,357 $71.9 Million
Q2 2020

Aug 14, 2020
SELL
$19.25 - $26.76 $3.41 Million - $4.75 Million
-177,361 Reduced 31.14%
392,152 $9.77 Million
Q1 2020

May 15, 2020
SELL
$12.8 - $27.05 $7.61 Million - $16.1 Million
-594,489 Reduced 51.07%
569,513 $12.1 Million
Q4 2019

Feb 14, 2020
SELL
$17.37 - $27.27 $6,948 - $10,908
-400 Reduced 0.03%
1,164,002 $25.8 Million
Q3 2019

Nov 14, 2019
SELL
$16.89 - $29.88 $74,316 - $131,472
-4,400 Reduced 0.38%
1,164,402 $26.5 Million
Q2 2019

Aug 14, 2019
BUY
$18.08 - $19.83 $21.1 Million - $23.2 Million
1,168,802 New
1,168,802 $22.4 Million

Others Institutions Holding AKRO

# of Institutions
168
Shares Held
72.7M
Call Options Held
178K
Put Options Held
164K
View Full List

About Akero Therapeutics, Inc.

AKRO Quotes by TradingView
  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.23B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email